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The current diagnosis of osteoarthritis (OA) relies on the description of pain symptoms, affected joint
stiffness, and radiography used as the reference technique for determining the grade of joint destruction.
Limitations of the presently available diagnostic tests have provided an impetus for the substantial in-
crease in interest in ﬁnding new speciﬁc biological markers for cartilage degradation to facilitate the
early diagnosis of joint destruction, evaluate disease progression and improve disease prognosis. Bio-
markers for OA are also useful for drug development, treatment monitoring, and as a basis for person-
alized evidence-based action plans. This review summarizes 29 manuscripts published during 2013 with
a focus on soluble biochemical biomarkers, primarily those utilizing proteomic, metabolomics, lipidomic
and imaging mass spectrometry technologies.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
An important objective for osteoarthritis (OA) research is the
conceptualization and development of early diagnostic strategies.
OA is clinically silent in most individuals during its initial stages,
therefore extensive deterioration of cartilage already exists at the
time of diagnosis. The current diagnosis of OA relies on the sub-
jective description of pain symptoms by patients, affected joint
stiffness, and radiography used as the reference technique for
determining the grade of joint destruction. Limitations of the
presently available diagnostic tests have provided an impetus for
the increased interest in ﬁnding new speciﬁc biological markers for
cartilage degradation to facilitate the early diagnosis of joint
destruction, evaluate disease progression and improve disease
prognosis.
A biomarker has been deﬁned as “a characteristic that is
objectively measured and evaluated as an indicator of normal
biologic processes, pathogenic processes, or pharmacologic re-
sponses to a therapeutic intervention.” Biomarkers for OA are also
useful for drug development, treatment monitoring, and as a basis
for personalized evidence-based action plans. This “Year in Review”rancisco J. Blanco, Servicio de
s 84, 15006 A Coru~na, Spain.
ternational. Published by Elsevier Lmanuscript will focus on soluble biochemical biomarkers, primarily
those studies utilizing proteomic and metabolomics technologies.
Methodology
Relevant articles and abstracts were identiﬁed through a
PubMed/MEDLINE and EMBASE search of English language articles
published between April 1, 2013 and April 1, 2014. The initial search
strategy included the terms: osteoarthritis, biomarker, biomarkers,
biological marker, proteomics, lipidomics, and metabolomics. The
initial search yielded 153 articles. Human studies were then given
preference over animal studies and biomarkers other than
biochemical biomarkers were eliminated from consideration.
Finally, 29 relevant articles were selected by the author according
to their quality. In this review, the descriptions of and comments on
the selected papers follow the phases of biomarker development
shown in Fig. 1.
Phase I: discovery phase
Biomarker research involves a series of steps moving from dis-
covery to the launch of a commercial biomarker product (Fig. 1).
Proteomics and metabolomics have generated great expectations
for discovery of biomarkers to improve the diagnosis of a wide
range of diseases. There are two general approaches for proteomic
biomarker discovery: global/nondirected and target-speciﬁc.
Because global/nondirected approaches are unbiased and high-td. All rights reserved.
Fig. 1. Phases of proteomics biomarkers development. The Discovery phase encompasses discovery and analytical validation sub-phases. The aim of the Discovery phase is to ﬁnd
prospective biomarkers using a small number of samples. The Development phase is composed of assay development, veriﬁcation and qualiﬁcation (clinical validation) sub-phases.
The aim of the Development phase is to deﬁne biomarker candidates and qualify/verify biomarkers using clinical application.
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biomarker discovery. There are also two strategies for nondirected
approaches: those that proﬁle unidentiﬁed proteins and those that
generate patterns of identiﬁed proteins. Proﬁling of unidentiﬁed
proteins often, but not always, utilizes matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometry (MALDI-
TOF-MS). Overall, the main advantage of nondirected approaches is
speed in processing many samples, making them highly advanta-
geous for clinical screening. However, target-speciﬁc approaches
frequently use antibodies to screen speciﬁc proteins by utilizing
western blot analysis, enzyme-linked immunosorbent assay
(ELISA), or antibody arrays, making them useful for validation in the
discovery phase (Fig. 1).
Blood (plasma and/or serum) and other body ﬂuids are excellent
sources of protein biomarkers for proteomic analyses because of
their contact with most tissues. Through this contact, body ﬂuids
pick up proteins secreted or shed by tissues. A major advantage of
using plasma and/or serum is ready availability. However, the
proteins secreted or released from a speciﬁc tissue or cell type that
hold the highest potential as biomarkers are often so diluted in
blood as to make them undetectable by current methods. This has
generated great interest on analyses focusing on “proximal” body
ﬂuids (i.e., synovial ﬂuid [SF]), those that contact only one or a few
tissues; thus less dilution of tissue-derived proteins would be
expected.
Biomarkers in discovery phase
Because SF bathes all the intrinsic structures of diarthrodial
joints, analyses of its constituents offer a unique opportunity to
study the entire diseased OA joint. Three papers, using different
approaches, have reported several biomarkers in SF1e3. Using two-
dimensional differential gel electrophoresis (2D-DIGE) and MS, 66
proteins were identiﬁed as differentially present in healthy and OA
SF1. Among these proteins, three major pathways were identiﬁed:
the acute phase response, and the complement and coagulation
pathways. An analysis focusing on those transcripts corresponding
to the proteins found to be differentially present also indicated that
synovial and cartilage tissues may both contribute to the OA SFproteome. This study also compared age-matched knee SF samples
from control subjects and patients with early- and late-stage OA
and found no important differences between the OA stages1.
High-resolution MS identiﬁed 545 proteins not previously re-
ported in OA SF2. However, multiple reaction monitoring (MRM)
analysis validated only three of these proteins, aminopeptidase N
(ANPEP), Dickkopf-related protein 3 (DKK3) and osteoglycin (OGN),
in ten OA SF samples. Further evaluations of some of these newly
identiﬁed proteins may reveal their potential as speciﬁc targets or
useful biomarkers for OA. The authors suggest that improved
knowledge of these proteins could provide insights into the un-
derlying mechanism of OA pathogenesis and lead to better thera-
peutic strategies2.
One of the major functions of SF in articular joints is lubrication
of the surfaces of cartilage, menisci, tendons, and ligaments.
Boundary lubrication by SF lowers the friction between apposed
and pressurized articular cartilage surfaces. SF contacts 10% of the
total joint area and is necessary to protect and maintain intact
cartilage surfaces. Three major components of SF have been pro-
posed to independently or additively mediate boundary lubrica-
tion: membrane phospholipids, lubricin, and hyaluronan (HA).
Despite the evidence that phospholipids are important boundary
lubricants, a complete qualitative and quantitative chemical anal-
ysis of all phospholipids in SF has only been possible since the
recent development of sophisticated lipidomic methods. This
technology has enabled the identiﬁcation of all known phospho-
lipid classes and many individual species in OA and rheumatoid
arthritis (RA) SF. Certain phospholipids may act as boundary lu-
bricants, while others perform functions, such as immune modu-
lation during inﬂammation, cartilage destruction, cell
differentiation, apoptosis, and signaling.
Quantitative differences were observed in 117 phospholipid
species in SF obtained from the knees of control subjects and pa-
tients with early and late OA and RA3. Compared to controls, SF
from patients with early and late OA had a higher content of total
phospholipids, major phospholipid classes, and phospholipid spe-
cies. .Furthermore, the concentrations of 66 phospholipid species
were signiﬁcantly altered depending on the stage of OA. These data
indicate that disease- and stage-dependent differences exist in the
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from patients with early and late OA and RA. These differences
could alter the lubrication and reactive oxygen species (ROS)-
scavenging functions of SF and, thus, modulate the inﬂammatory
status of joints. These authors suggest that certain phospholipids,
including phosphatidylcholine, lysophosphatidylcholine, and
plasmalogens, may have an association, to some extent, with the
pathogenesis of OA and RA3.
A complementary lipidomic study of SF quantiﬁed the compo-
sition of sphingolipids (sphingomyelins, ceramides, and hexosyl-
and dihexosylceramides) and minor glycerophospholipid species
[(lyso)phosphatidic acid, (lyso)phosphatidylglycerol, and bis(mo-
noacylglycero)phosphate] in knee joint SF from unaffected control
subjects and from patients with early and late OA and RA4. The
results showed that concentrations of phospholipid species
increased in the knee joint SF of RA and OA patients compared with
those from the controls. A broad spectrum of sphingolipid species,
their precursors, and intermediate metabolites was found in hu-
man knee SF. Moreover, the concentration of 41 lipids in early OA
SF, 48 species in late OA SF, and 50 species in RA SF increased
signiﬁcantly in comparisonwith control SF. Notably, the levels of 21
lipid species were altered between early OA and late OA SF, indi-
cating that the lipid composition of SF reﬂects the severity of OA
disease. Accordingly, these results may lead to the development of
biomarkers able to discriminate healthy joints from those with
early OA and early OA joints from those with late OA4.
Using a liquid chromatography tandemMS (LC-MS/MS) analysis
approach, a very interesting study investigated the fatty acids and
their oxygenated derivatives (oxylipins) secreted by the infrapa-
tellar fat pad (IPFP) in end-stage OA and normal donors5. The IPFP is
a special form of adipose tissue located intracapsularly and extra-
synovially in the joint, existing in close contact with synovial layers
and articular cartilage. The IPFP facilitates SF distribution and ab-
sorbs mechanical forces through the knee. Adipose tissue adipo-
cytes and inﬁltrating immune cells actively secrete numerous
cytokines and adipokines, which in turn inﬂuence metabolism and
inﬂammatory responses in the body. Thus, these adipose tissue-
derived factors may contribute to the development of OA. This
metabolomics study found that 29 oxylipins and fatty acids were
detectable in fat-conditioned media (FCM)5. Statistical analyses
revealed an oxylipin/fatty acid proﬁle consisting of 14 mediators
associatedwith end-stage OA (accuracy rate 72%). Among these, the
most important contributors to the model were lipoxin A4
(decreased), thromboxane B2 (increased), and arachidonic acid
(increased). The statistical model correctly predicted 64% of the
mediators found in a second set of OA samples. The signiﬁcance of
this study was the demonstration that the OA IPFP and the normal
IPFP generate multiple and different oxylipins5.
A MS-based metabolic phenotype study identiﬁed global
metabolic defects associated with OA, as well as metabolic signa-
tures of three other types of arthritis: RA, ankylosing spondylitis
and gout, comparing sera from all forms of arthritis with those from
healthy controls6. The use of a combination of gas chromatography
coupled with TOF MS (GC-TOF MS) and ultra performance liquid
chromatography quadrupole-TOF MS (UPLC-QTOF MS) identiﬁed
196 metabolites in these sera. Metabolic defects common to these
forms of arthritis resulting from joint inﬂammation and lesions are
suggested by the identiﬁcation of a global metabolic proﬁle among
all arthritic subjects. Additionally, differentially expressed serum
metabolites were identiﬁed, providing a unique metabolic signa-
ture for each type of arthritis; these metabolic signatures may
prove useful as biomarkers for disease diagnosis and patient
stratiﬁcation. The metabolites, 5-oxoproline, tyrosine, citric acid,
lysine, acetylornithine, tryptophan, sarcosine, alanine and cis-aconitic acid, represent a metabolic signature that enabled the
authors to distinguish OA sera from RA or control sera6.
Several proteomics studies have been conducted using cartilage
or chondrocytes. Because the medial femur condyle is usually more
affected than the lateral condyle in OA, a quantitative comparison
was made between the secretomes of the medial and lateral femur
condyle chondrocytes in the same knee7. This same comparison of
medial/lateral femur condyle chondrocytes was also made on
secretomes from chondrocytes taken from one individual with no
clinically apparent joint disease, as well as from OA patients. The
authors identiﬁed 825 proteins in the secretome from OA chon-
drocytes; 69 of these proteins were differentially expressed when
medial and lateral femoral compartments were compared. Several
proteins of interest were identiﬁed and relatively quantiﬁed, CYTL1
(cytokine-like 1 protein), DMD (dystrophin) and STAB1 (signal
transducer and activator of transcription 1) for the OA disease
mechanism, and TIMP1 (tissue inhibitor of metalloproteinases-1),
PPP2CA (protein phosphatase 2A catalytic subunit), and B2M
(beta-2-microglobulin) as putative early OA disease markers. In this
study, the ﬁndings of differences in protein abundance between
medial and lateral femur condyles in OA patients are in accordance
with results of other studies suggesting that there are also differ-
ences in protein abundance between cartilage from knee and hip.
These ﬁndings expand our knowledge of biomarkers of OA found in
different locations.
Another classical proteomic approach using a quantitative
methodology (iTRAQ, or isobaric tags for relative and absolute
quantitation) was performed in articular cartilage from patients
with OA, using patients with femoral neck fracture for controls8.
This study identiﬁed 76 proteins with expression levels in OA pa-
tients differing from those of the control group. Among these
proteins, LECT2 (leukocyte cell-derived chemotaxin-2), BAALC
(brain and acute leukemia, cytoplasmic), and PRDX6 (peroxir-
edoxin-6), are worthy of note because they have not previously
been reported as biomarkers for OA8.
During the 2014 Osteoarthritis Research Society International
(OARSI) meeting in Paris, new and exciting methodologies were
presented to assist in the discovery of new biomarkers. One of these
was nucleic acid programmable protein arrays (NAPPA) technol-
ogy9; this is a new generation of self-assembled protein micro-
arrays to detect auto-antibodies (Fig. 2). Recent reports show
activation of pro-inﬂammatory pathways by extracellular matrix
(ECM) proteins, leading to their being named damage-associated
molecular patterns (DAMPs). This abnormal metabolic activity
can be speciﬁcally detected by the immune system, leading to a
humoral immune response producing immunoglobulins (auto-an-
tibodies) against these proteins. Auto-antibodies, which are stable
circulating proteins easily measurable in serum, may be detectable
before clinical manifestations of disease. Therefore, serum auto-
antibody proﬁling may facilitate the discovery of OA diagnostic,
prognostic or progression biomarkers. Utilizing NAPPA, autoim-
munity proﬁles measuring the speciﬁcities of the IgG repertoire in
serum from OA and RA patients, as well as healthy controls, were
presented in Paris as an abstract9. The analysis of auto-antibody
levels revealed immunoreactivity against seven full-length pro-
teins with signiﬁcant differences between OA, RA and control
samples. The proteins were identiﬁed as CD44 (CD44 antigen),
CHST14 (carbohydrate sulfotransferase 14), LEP (leptin), PCOLCE
(procollagen C-endopeptidase enhancer 1), IGFBP4 (insulin-like
growth factor-binding protein 4), IGFBP6 and IL-6 (interleukin-6).
Interestingly, although OA is not a classical autoimmune disease,
the detection of auto-antibodies is possible and methodologies
such as NAPPA could be useful for characterizing disease-speciﬁc
autoimmunity proﬁles used as high-value biomarkers.
Fig. 2. NAPPA. cDNAs encoding human proteins with a tag, are spotted onto chemically modiﬁed surfaces. In the NAPPA, full-length proteins are produced in situ, at the moment of
assay, using mammalian in vitro expression systems. The nascent protein is captured by immobilized antibodies speciﬁc for a tag encoded at the carboxy-terminus of the amino acid
sequence, which ensures full-length translation of the captured protein. The immunogenicity observed with NAPPA is related to the epitope of the folded protein exposed to its
speciﬁc auto-antibody. Thus, in NAPPA, the different folding in the expression leads to the detection of different immunogenicity results and also includes the possibility of
identifying conformational epitopes.
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at OARSI 2014 was MALDI-imaging MS (MALDI-IMS). MALDI-IMS is
a new imaging technology for the study of tissues10e12 that can
determine the distribution of hundreds of unknown compounds in
a singlemeasurement and, as such, can assist in the localization and
identiﬁcation of key molecules in OA pathology. In recent years,
MALDI-IMS has been used to search for speciﬁc peptides, proteins
and lipids in precise areas of a tissue cartilage sectionwith a spatial
resolution below 50 mm (Fig. 3). This methodology has now been
used to study lipidomic distribution and modulation during the
chondrogenesis process in human bone marrow mesenchymal
stem cells (MSCs) and in the OA synovial membrane. The MALDI-
IMS analysis of MSC micromasses at days 2 and 14 of chondro-
genesis identiﬁed 20 different lipid species, including fatty acids,
sphingolipids and phospholipids. In the undifferentiated chondro-
genic stage, levels of phosphocholine, several sphingomyelins and
phosphatidylcholines were increased. In the OA synovia, proteins,
such as hemoglobin subunit alpha 2, hemoglobin subunit beta,
actin aortic smooth muscle, biglycan and ﬁbronectin have been
identiﬁed and localized in areas of high inﬂammation. In addition,
cluster analyses revealed that peaks assigned to diacylglycerols and
actin were grouped as molecular signatures speciﬁc to normal
tissues.
Many “omics” technologies, including microarrays, next gener-
ation sequencing and MS, generate large amounts of data. There-
fore, bioinformatics tools play an increasingly important role in the
analysis of such data and a wide range of methods has been
developed for this purpose. Supervised machine learning tech-
niques, based on a training set of labeled samples, are used to build
models capable of automatically labeling previously unclassiﬁed
samples. Samples can be assigned a label (e.g., a treatment group)
based on whether they contain a certain attribute (e.g., a protein or
group of proteins) and the level of this attributewithin the samples.
Two very interesting works, a paper and an abstract, have focused
on this topic13,14. The aim of the paper was to identify suitablebioinformatics methods for the analysis of proteomics data gener-
ated from an investigation of cytokine-induced catabolic changes
associated with the early stages of OA13. This study used an explant
model of cartilage to investigate the secretome of canine articular
cartilage. BioHEL, a rule-based machine learning and analysis
technique, was applied to proteomic MS data to create models that
classiﬁed samples into their relevant treatment groups by identi-
fying those proteins that separated samples into their respective
groups. BioHEL correctly classiﬁed eighteen of twenty-three sam-
ples, a classiﬁcation accuracy of 78.3% for the dataset. Among the
proteins identiﬁed and most frequently used in rules generated by
BioHEL, the relevant proteins included MMP-3 (matrix metal-
loproteinase 3), IL-8 (interleukin-8) and matrix gla protein. These
studies support the application of bioinformatics tools for the
analysis of proteomic data.
Phase II: development phase
This phase of biomarker development stems from a general
understanding of the pathophysiology of a disease. Not surpris-
ingly, biomarker development in OA is escalating as we gain a
deeper knowledge of the disease, its stages, and its various phe-
notypes. A three-part framework for biomarker evaluation has
been described that requires answers to speciﬁc questions1: Assay
Development/Analytical validation d Is the biomarker accurately
measurable?2; Veriﬁcationd Is the biomarker associated with the
clinical endpoint of concern?; and 3 Qualiﬁcation (Clinical Valida-
tion)dWhat is the speciﬁc context of the proposed use and what is
the sensitivity and speciﬁcity in population-derived human
samples?
Biomarkers in assay development
This phase is characterized by development of sensitive
biomarker assays, essential tools for analysis of patient samples and
Fig. 3. Matrix assisted laser desorption ionization imaging- Imaging mass spectrometry (MALDI-IMS). After careful preparation, the tissue section is introduced into the mass
spectrometer and the proteins, peptides and lipids are desorbed from discrete pixels from the surface in an ordered way. Each pixel is thus linked to the mass spectrum speciﬁc from
that region. A plot of the intensity of each signal produces a map of the relative abundance of that compound over the imaged tissue.
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joint injuries. Four studies have developed different tools for
detection and quantiﬁcation of biomarkers in urine, serum and
SF15e18.
Two studies focus on the analysis of aggrecan ARGS neo-
epitopes15,16. Quantiﬁcation of ARGS-aggrecan in SF is a more
sensitive tool for distinguishing diseased and injured joints from
healthy joints than quantiﬁcation of total aggrecan or other
aggrecanase-generated fragments. Aggrecan fragments in SF have
been characterized by western blot, but much less is known about
the structure of aggrecan fragments in plasma and serum. There are
ﬁve known aggrecanase cleavage sites, and in terms of destructive
loss of sulfated glycosaminoglycans from the cartilage matrix, the
most severe cleavage is at the 392Glu-393Ala bond within the
aggrecan inter-globular domain (IGD). This cleavage releases N-
terminal 393ARGS neoepitope aggrecan fragments into SF. In the
ﬁrst study, the authors describe and characterize an ARGS-aggrecan
electrochemiluminescence (ELCL) assay with modiﬁcations result-
ing in a two-fold increased sensitivity compared to a previous
version; this technique is capable of quantiﬁcation of the ARGS neo-
epitope in SF, serum, and plasma15.
In an observational study, the authors evaluated the ARGS
neo-epitope in patients with knee OA to support development of
GSK2394002 and other drugs that may affect cartilage degrada-
tion16. This study focused on the assessment of the performance
of the ARGS neo-epitope assay and the determination of relative
concentrations of the ARGS neoepitope in blood, SF and urine ofpatients with knee OA. These patients had either been managed
conservatively with OA conﬁrmed by X-ray but not scheduled or
anticipated to require joint replacement in the coming year, or
had end-stage knee OA and were undergoing total knee
replacement. Correlations between serum and SF ARGS neo-
epitope concentrations with other demographic or clinical factors
were assessed. A set of samples obtained from age- and sex-
matched healthy volunteers served as a control group. Data
from this study inform and facilitate biomarker strategy and
study design of disease-modifying treatments of OA. In addition,
ARGS neo-epitope measurements have potential to serve as
prognostic or stratiﬁcation markers to identify patient subsets
more likely to respond to and beneﬁt from speciﬁc treatment
regimes16.
The third study quantiﬁed the activity of an arthritis-associated
HA binding protein, tumor necrosis factor-a (TNF-a)-stimulated
gene-6 (TSG-6) in SF17. Because a TSG-6 ELISA adequately sensitive
and speciﬁc to be used with biological ﬂuids is not currently
available, these authors developed an assay to measure TSG-6 ac-
tivity in SF under conditions very close to in vivo conditions. The
association of TSG-6 activity, determined retrospectively in SFs
collected at baseline, was analyzed with data from a prospective
natural history study of OA progression. The authors suggest that
TSG-6 activity is a promising independent biomarker for OA pro-
gression that may be particularly useful for identifying those pa-
tients at low risk for rapid disease progression and for providing
guidance for the timing of arthroplasty17.
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established the reference interval range of 18 biomarkers. Tradi-
tionally, reference ranges for biomarkers are determined using
commercially purchased blood from normal donors. This source
does not provide adequate controls for OA studies because the
normal donor OA status is not ascertained. The authors deﬁned the
concept of “supercontrol” subjects, thosewho have no radiographic
evidence of OA of the knee, hip, hand, and spine and no knee or hip
symptoms (pain, aching or stiffness on most days)18.
Biomarkers in veriﬁcation phase
Veriﬁcation studies must determine whether the biomarker is
associated with any clinical endpoint. Relative to this requirement,
several published studies have analyzed the role of inﬂammatory
biomarkers in knee pain19,20. Knee pain is associated with body
mass index (BMI) and knee structural changes, such as cartilage
defects, bone marrow lesions (BML), synovitis, joint effusion and
osteophytes. The positive associations between synovitis/effusion
and knee pain indicate that inﬂammation may be involved in its
genesis. One of these studies examined the association between
levels of inﬂammatory biomarkers and changes in knee pain in
community-based older adults over a 5-year time interval19. The
results of this study indicate that changes from baseline in high-
sensitivity C-reactive protein (hs-CRP) over 5 years and TNF-a
over 2.7 years were associatedwith increased knee pain as assessed
by the total Western Ontario and McMaster Universities Arthritis
Index (WOMAC) score. Interestingly, hs-CRP woas found to be
associated with increased knee pain when lying in bed and sitting,
while TNF-a and IL-6 predicted greater knee pain when standing19.
A translational study compared the effects of diet-induced
weight loss plus exercise (D þ E), diet-induced weight loss only
(D), and exercise only (E) interventions on mechanistic (knee-joint
compressive force, IL-6 levels) and clinical outcomes (pain, function,
mobility, health-related quality of life [HRQL]) in overweight and
obese adults with knee OA20. The results of this study showed that
after 18 months, those overweight and obese adults with knee OA in
the diet and exercise group had more weight loss and a greater
reduction in IL-6 levels than those in the exercise only group20.
Another series of studies examined the role of bone and carti-
lage biomarkers in OA. OA is a disease of the whole joint, affecting,
besides articular cartilage, the juxta-articular bone, including
osteophyte formation and subchondral changes that ﬁnally lead to
sclerosis. Historically, two decades ago the suggestion was made
that bone rather than cartilage may be responsible for the initial
pathophysiological events in OA. Moreover, the potent inhibitors of
bone resorption, bisphosphonates, have been shown to reduce
cartilage degeneration, osteophyte formation and bone resorption
in both experimental animal models of OA and in human OA.
One of these studies simultaneously investigated the synthetic,
resorptive and mineralization aspects of bone metabolism in early-
stage progressive and non-progressive knee OA21. The study
assayed speciﬁc markers of bone formation (procollagen I N-ter-
minal peptide [PINP]) and bone resorption (C-terminal cross-linked
telopeptides of type I collagen [CTx-I]), as well as a non-collagenous
marker of bone mineralization (osteocalcin [OC]), and a novel non-
collagenous marker of bone resorption, urinary midfragments of
OC (MidOC). Enhanced bone formation (shown by PINP), together
with bone formation activation (also shown by PINP) and non-
collagenous bone resorption (shown by MidOC), as well as bone
mineralization (shown by OC) preceded OA progression. All bone
markers assessed, PINP, OC, and MidOC, demonstrated diagnostic
value, and PINP also had predictive value for knee OA progression,
particularly progressive osteophytosis. Another work collected
radiographic knee OA (RKOA) data over 10-years in a largecommunity-based sample of middle-aged British females22. This
study investigated whether circulating levels of cartilage oligo-
meric matrix protein (COMP), aggrecan, N-terminal telopeptide
(NTx) and cellular inhibitor of apoptosis protein (cIAP) are predic-
tive of the appearance of RKOA-associated phenotypes. Among
these biomarkers, the results of this study indicate that the inci-
dence of some RKOA phenotypes could be predicted by circulating
levels of aggrecan and COMP. Analyses of joint space narrowing
data led these authors to suggest that aggrecan plays a protective
role against cartilage loss while the association of COMP circulating
levels with KellgreneLawrence (K/L) grades suggests that a high
COMP level is a risk factor for development of RKOA22.
One problem affecting biomarker studies has been the use of
small sample sizes and caseecontrol designs with cases recruited
from secondary care settings. To address these limitations, a meta-
analysis combining data from three large population-based cohorts
(the Rotterdam Study, the Genetics osteo-Arthritis and Progression
(GARP) and the Chingford Study) and one familial study of OA (the
TwinsUK) was performed using hand, knee and hip X-rays. Samples
from 3582 individuals were measured for three separate cartilage-
based biomarkers (urinary C-terminal telopeptide [uCTX-II], serum
COMP (sCOMP), and serumMMP degraded type II collagen [sC2M])
to enable assessment of the efﬁcacy of biomarkers to measure
prevalence, incidence and progression of OA and to assess the
prognostic value of these biomarkers. Because levels of uCTX-II
were signiﬁcantly associated with risk of hand, hip and knee OA,
and progression and incidence of knee OA, the authors concluded
that the most informative biochemical marker for prediction of OA
was uCTX-II. Levels of sCOMP were found to be associated with
knee OA and hip and knee OA incidence, while levels of sC2M were
associated with OA incidence and progression; the authors suggest
that these markers describe disease activity23.
In 2013, the role of biomarkers for hand radiological OA has also
been studied. One study investigated the age-related characteris-
tics of two putative OA biomarkers (sCOMP and urinary crosslinked
C-telopeptide of type II collagen [uCTX2]), in healthy aging in-
dividuals (healthy agers), in patients with OA at multiple joint sites,
and in a control population24. The study found that being a middle-
aged metabolically healthy ager was associated with less radio-
graphic OA and that the inﬂuence of metabolic health on OA
biomarker proﬁles was not age-related. Independent of hand
radiographic OA status, the OA biomarker, uCTX2, was inﬂuenced
by healthy metabolism and the OA biomarker, sCOMP, increased
with advancing age. Compared with age-matched controls of
similar BMI, the age-related increase in prevalence of hand radio-
graphic OAwas lowered in healthy agers. In addition, glucose levels,
representing metabolic health, were shown to partially account for
this effect. This study concludes that the use of potential OA bio-
markers, including sCOMP and uCTX2, for the diagnosis and
monitoring of OA, should take important metabolic properties and
chronological age into consideration in the development of effec-
tive disease-modifying treatments24.
A cross-sectional study of hand OA determined the associations
between multiple joint metabolism biomarkers and hand radio-
graphic OA, symptoms, and function in 663 participants25. Meta-
carpophalangeal (MCP) and carpometacarpal radiographic OA and
a higher number of hand joints with radiographic OA were all
signiﬁcantly associated with higher levels of serum HA (sHA). The
levels of the biomarkers, sCOMP and sHA, were positively associ-
ated with the Australian Canadian Hand Osteoarthritis Index
(AUSCAN) scores and hand symptoms, while hand symptoms and
higher AUSCAN scores were independently associated with higher
levels of both sCOMP and sHA25.
Pre-radiographic OA is a very interesting and existent ﬁeld. It is
well known that patients with anterior cruciate ligament (ACL)
F.J. Blanco / Osteoarthritis and Cartilage 22 (2014) 2025e2032 2031deﬁciency are at an increased risk for the development of OA. The
prevalence of knee OA is lower in individuals with an isolated ACL
injury (0 vs 13%) and higher in subjects with combined injuries (21
vs 48%). The most frequently reported risk factor for the develop-
ment of knee OA ismeniscal injury. Based on these data, a new study
determined whether there was an association between biomarkers
measured in SF and damage to articular cartilages and/or menisci26.
These investigators examined 108 knee joints arthroscopically in the
period following ACL injury and before the development of radio-
graphic changes. The biomarkers studied in SF were cartilage type II
collagen collagenase-generated cleavage neoepitope (C2C biomarker
assay) and disaccharides of the glycosaminoglycans chondroitin
sulfate (CS) and keratan sulfate (KS) that are mainly present in
articular cartilages on the proteoglycan aggrecan. In this study
population, the presence of multi-high grade cartilage lesions was
strongly associated with a combination of deﬁned ranges (quartiles)
of the C2C and KS biomarkers; this impact was independent of
clinical variables and exceeded the impact of the individual bio-
markers. The authors suggest the value of the use of combinations of
biomarkers and deﬁned quartiles in future clinical trials.
A very interesting paper that studied similarities between
CTX-II and bone markers suggested that CTX-II is not only a
marker of cartilage degradation27. In the CHECK (Cohort Hip and
Cohort Knee) study of early OA, ELISAs were used to determine
levels of the putative cartilage marker, uCTX-II, and bone markers
(urinary C-terminal propeptide of type I collagen [uCTX-I], uri-
nary cross-linked N telopeptide of type I collagen [uNTX-I],
serum N-terminal propeptide of type I collagen [sPINP], and
serum OC [sOC]) and other cartilage markers (sCOMP, serum
CS846 [sCS846], and serum type IIA procollagen amino terminal
propeptide [sPIIANP]). Intriguingly, the results of this study
revealed that the putative marker of cartilage degradation, uCTX-
II was more strongly associated with markers of bone meta-
bolism than with markers of cartilage metabolism; this strong
association with bone markers was not found with the other
cartilage markers. Additionally, an abrupt menopausal shift in
women aged 48e53 years was seen in levels of both uCTX-II and
the bone markers, but not with the other cartilage markers, even
when adjusted for age and BMI. Although the association be-
tween uCTX-II and the bone markers could be ascribed to the
metabolic and biomechanical mechanistic links between carti-
lage and bone metabolism, this association was not shared by the
other cartilage markers. This unique relationship of uCTX-II with
bone markers may indicate the metabolism of bone rather than
cartilage. The authors suggest that further validation of uCTX-II
as a biomarker is required27.
Biomarkers have also been evaluated in a clinical trial. A pilot
clinical trial assessed changes in walking pain and serum levels of
two OA biomarkers suggested to reﬂect oxidative-related cartilage
degradation: the a-helical region of type II collagen (Coll2-1) and its
nitrated form (Coll2-1 NO2), following viscosupplemenation (VS).
Knee osteoarthritis patients (n ¼ 51) with unilateral symptoms
were followed for 3months following three intra-articular in-
jections of HA28. At baseline, serum concentrations of Coll2-1 and
Coll2-1 NO2, measured using speciﬁc immunoassays, were signif-
icantly higher in K/L grade III/IV patients compared to K/L grade I/II
patients. These levels decreased over time after VS. The effect of VS
was most pronounced in patients with KL III/IV, suggesting a rapid
slowdown of type II collagen degradation and joint inﬂammation
after VS with HA. The study also revealed that the serum concen-
tration of Coll2-1 was signiﬁcantly lower at baseline in responders
than in non-responders, and the authors suggest that serum levels
of Coll2-1 may be to be a predictive factor for response to treat-
ment. This study was an open, non-controlled, pilot clinical trial
with only 51 patients, and, although these results are interesting,they must be conﬁrmed by a controlled and double-blind clinical
trial using larger numbers.
In summary, in addition to the papers included in this review,
several other interesting papers and abstracts in the ﬁeld of
biochemical biomarkers and OA (See review29) were published in
the year 2013. Novel biomarkers have been discovered and newand
exciting methodologies are used every day in the discovery phase,
including metabolomics, lipidomics, imaging mass spectrometry
and NAPPA. Several innovative assays have been developed to study
biomarkers in SF, serum and urine; and various studies have been
carried out in the veriﬁcation phases. But we need more energetic
efforts for more biomarkers to reach the qualiﬁcation phase.
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